New concepts in pathogenesis of renal hypophosphatemic syndromes

Iranian Journal of Kidney Diseases

Volumn 3, Issue 1, 2009, Pages 1-6

  Rastegar, Asghar ^a  

^a NONE   (United States)

Author keywords

Hypophosphatemia; Osteomalacia; Phosphates metabolism; Vitamin D resistant rickets

Indexed keywords

CARRIER PROTEIN; FIBROBLAST GROWTH FACTOR 23; PHOSPHATONIN; UNCLASSIFIED DRUG;

BONE DEVELOPMENT; BONE MINERALIZATION; HUMAN; HYPERCALCIURIA; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; KIDNEY DISEASE; KIDNEY FUNCTION; NONHUMAN; OSTEOMALACIA; PATHOGENESIS; PHOSPHATE BALANCE; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PROTEIN FUNCTION; RENAL HYPOPHOSPHATEMIC SYNDROME; REVIEW; SODIUM TRANSPORT; VITAMIN BLOOD LEVEL;

FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIA; KIDNEY; MUTATION; PHOSPHATES; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS; SYNDROME; VITAMIN D;

EID: 64549113761     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Gaasbeek A, Meinders AE. Hypophosphatemia: an update on its etiology and treatment. Am J Med. 2005;118:1094-101.
2. Amanzadeh J, Reilly RF, Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol. 2006;2:136-48.
3. Murer H, Forster I, Biber J. The sodium phosphate cotransporter family SLC34. Pflugers Arch. 2004;447:763-7.
4. Favus MJ. Intestinal absorption of calcium, magnesium and phosphorus. In: Coe FL, Favus MJ, editors. Disorders of bone and mineral metabolism. 2nd ed. New York: Lippincott Williams and Wilkins; 2002. p. 48-73.
5. Segawa H, Kaneko I, Yamanaka S, et al. Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. Am J Physiol Renal Physiol. 2004;287:F39-47.
6. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev. 2000;80:1373-409.
7. Bacic D, Lehir M, Biber J, Kaissling B, Murer H, Wagner CA. The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone. Kidney Int. 2006;69:495-503.
8. Keusch I, Traebert M, Lötscher M, Kaissling B, Murer H, Biber J. Parathyroid hormone and dietary phosphate provoke a lysosomal routing of the proximal tubular Na/Pi-cotransporter type II. Kidney Int. 1998;54:1224-32.
9. Pastoriza-Munoz E, Mishler DR, Lechene C. Effect of phosphate deprivation on phosphate reabsorption in rat nephron: role of PTH. Am J Physiol. 1983;244:F140-9.
10. Stoll R, Kinne R, Murer H, Fleisch H, Bonjour JP. Phosphate transport by rat renal brush border membrane vesicles: influence of dietary phosphate, thyroparathyroidectomy, and 1,25-dihydroxyvitamin D3. Pflugers Arch. 1979;380:47-52.
11. Gloor HJ, Bonjour JP, Caverzasio J, Fleisch H. Resistance to the phosphaturic and calcemic actions of parathyroid hormone during phosphate depletion. Prevention by 1,25-dihydroxyvitamin D3. J Clin Invest. 1979;63:371-7.
12. Faroqui S, Levi M, Soleimani M, Amlal H. Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia. Kidney Int. 2008;73:1141-50.
13. Cai Q, Hodgson SF, Kao PC, et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994;330:1645-9.
14. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500-5.
15. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656-63.
16. Fukumoto S. Physiological regulation and disorders of phosphate metabolism-pivotal role of fibroblast growth factor 23. Intern Med. 2008;47:337-43.
17. Berndt TJ, Schiavi S, Kumar R. "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol. 2005; 289:F1170-82.
18. Berndt TJ, Kumar, R. Phosphatonins and the regulation of phosphate homeostasis. Ann Rev Physiol. 2007;69:341-59.
19. AHDR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26:345-8.
20. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60:2079-86.
21. Bai XY, Miao D, Goltzman D, Karaplis AC. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem. 2003;278:9843-9.
22. [No authors listed]. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995;11:130-6.
23. Yuan B, Takaiwa M, Clemens TL, et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest. 2008;118:722-34.
24. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet. 2006;38:1248-50.
25. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90:1519-24.
26. Sommer S, Berndt T, Craig T, Kumar R. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol. 2007;103:497-503.
27. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305-15.
28. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272-9.
29. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120-3.
30. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem. 2008;389:233-41.
31. Segawa H, Yamanaka S, Ohno Y, et al. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol. 2007;292:F769-79.
32. Brownstein CA, Adler F, Nelson-Williams C, et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci U S A. 2008;105:3455-60.
33. Bergwitz C, Roslin NM, Tieder M, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet. 2006;78:179-92.
34. Jaureguiberry G, Carpenter TO, Forman S, Jueppner H, Bergwitz C. A novel missense mutation in SLC34A3 that causes HHRH identifies threonine 137 as an important determinant of sodium-phosphate co-transport in NaPi-IIc. Am J Physiol Renal Physiol. 2008;295:F371-9